GAVI's new half-price vaccines deal will protect more children

19 October 2016
vaccinebig

GAVI, the Vaccine Alliance, which was co-founded by Bill Gates in 2000, has secured a record cost-cutting vaccine deal, the organization announced today.

This will ensure sufficient supplies for the next three years to protect millions of children in GAVI-supported and transitioning countries. Moreover, pentavalent vaccine – a cornerstone of routine immunization programs – will be accessible from a broad base of manufacturers at less than $1: half this year’s average price.

“We estimate that pentavalent vaccination will avert 5.7 million deaths in GAVI-supported countries between 2011 and 2020,” said Dr Seth Berkley, chief executive of GAVI. “The market for five-in-one vaccines is now a lot healthier than it was just a few years ago thanks to our collective efforts to grow a base of vaccine suppliers. We remain committed to making vaccine markets work better for the world’s poorest countries to ensure immunization investments and efforts are sustainable for all,” he noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical